Cancer Research Institute
Clinical Trials
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan
Versus Treatment of Physician’s Choice in Patients With Previously
Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative
Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients
Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose
Tumors Do Express PD-L1
Versus Treatment of Physician’s Choice in Patients With Previously
Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative
Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients
Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose
Tumors Do Express PD-L1
This study is currently enrolling.
This study will be recruiting patients with previously untreated, locally advanced, inoperable or metastatic Triple-Negative Breast Cancer whose tumors do not express PD-L1 or patients previously treated with Anti PD-(L)1 Agent ...
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and
Pembrolizumab Versus Treatment of Physician’s Choice and
Pembrolizumab in Patients With Previously Untreated, Locally Advanced,
Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors
Express PD-L1.
Pembrolizumab Versus Treatment of Physician’s Choice and
Pembrolizumab in Patients With Previously Untreated, Locally Advanced,
Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors
Express PD-L1.
This study is currently enrolling.
The purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve lifespans of patients with advanced, PD-L1 positive TNBC and their tumor does not grow or spread when compared to chemot ...
ACE-536-MF-002: A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)
This study is currently enrolling.
The main purpose of this study is to see if people with MPN-associated myelofibrosis that need blood transfusions will stop needing RBC transfusions or require less frequent RBC transfusions by taking luspatercept. The safety ...
AN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS
This study is currently enrolling.
AN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS
AV-299-23-301: A Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Subjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma
This study is currently enrolling.
The main purpose of this study is to investigate the safety, effectiveness, and tolerability (whether side effects can be handled by a participant) of ficlatuzumab at two different doses when given with the established dose of ...
AV-380-22-102: A Phase 1 Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients with Cachexia and Elevated GDF-15 Levels
This study is currently enrolling.
The study involves research. The purpose of the study is to see if a single dose and multiple doses of the study drug, AV 380, are safe and tolerated in cancer participants. This study will also help to look at how AV 380 behav ...
BT8009-100: Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies
This study is currently enrolling.
CB-010: A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
This study is currently enrolling.
Allogeneic CAR-T cell therapy is a type of cancer therapy in which a healthy donor’s T cells (a type of immune system cell that circulates in blood) are modified during manufacturing using CRISPR genome editing so that those T ...
CIRB/COG AAML1531 Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
This study is currently enrolling.
The overall goals of this study are to: To find out if subjects with standard risk DS AML can be treated with less treatment and still have successful outcomes. To find out if subjects with high risk DS AML can be successfully ...